Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

The recent approval of anti-programmed death-ligand 1 immunotherapy in combination with nab-paclitaxel for metastatic triple-negative breast cancer (TNBC) highlights the need to understand the role of chemotherapy in modulating the tumor immune microenvironment (TIME). We examined immune-related gen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2020-11, Vol.26 (21), p.5668-5681
Hauptverfasser: Axelrod, Margaret L, Nixon, Mellissa J, Gonzalez-Ericsson, Paula I, Bergman, Riley E, Pilkinton, Mark A, McDonnell, Wyatt J, Sanchez, Violeta, Opalenik, Susan R, Loi, Sherene, Zhou, Jing, Mackay, Sean, Rexer, Brent N, Abramson, Vandana G, Jansen, Valerie M, Mallal, Simon, Donaldson, Joshua, Tolaney, Sara M, Krop, Ian E, Garrido-Castro, Ana C, Marotti, Jonathan D, Shee, Kevin, Miller, Todd W, Sanders, Melinda E, Mayer, Ingrid A, Salgado, Roberto, Balko, Justin M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!